MCID: OVR114
MIFTS: 62

Ovarian Cancer 1

Categories: Endocrine diseases, Reproductive diseases, Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Ovarian Cancer 1

MalaCards integrated aliases for Ovarian Cancer 1:

Name: Ovarian Cancer 1 57 29
Ovarian Carcinoma 12 15 73
Ovarian Cancer, Susceptibility to 57 13
Ovarian Cancer, Susceptibility to, 1 57
Malignant Neoplasm of Ovary 73
Ovarian Epithelial Cancer 44
Epithelial Ovarian Cancer 73
Ovarian Cancer 57
Ovcas1 57

Classifications:



External Ids:

OMIM 57 607893
Disease Ontology 12 DOID:4001
MeSH 44 C538090
NCIt 50 C4908

Summaries for Ovarian Cancer 1

MalaCards based summary : Ovarian Cancer 1, also known as ovarian carcinoma, is related to hereditary breast ovarian cancer syndrome and ovarian cancer, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer 1 is OVCAS1 (Ovarian Cancer, Epithelial, Susceptibility To), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs CEA-Scan and Doxil have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and ovary, and related phenotypes are Decreased viability in esophageal squamous lineage and homeostasis/metabolism

Description from OMIM: 607893

Related Diseases for Ovarian Cancer 1

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Ovarian Benign Neoplasm

Diseases related to Ovarian Cancer 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)
# Related Disease Score Top Affiliating Genes
1 hereditary breast ovarian cancer syndrome 34.9 BRCA1 BRCA2 TP53
2 ovarian cancer 31.8 BRCA1 BRCA2 CDH1 DPH1 ERBB2 FILIP1L
3 ovarian epithelial cancer 12.3
4 breast-ovarian cancer, familial 1 12.2
5 breast-ovarian cancer, familial 2 12.2
6 breast-ovarian cancer, familial 3 12.2
7 breast-ovarian cancer, familial 4 12.2
8 childhood ovarian cancer 12.2
9 brca2 hereditary breast and ovarian cancer syndrome 12.1
10 hereditary site-specific ovarian cancer syndrome 11.1 BRCA1 BRCA2
11 breast reconstruction 11.0 BRCA1 BRCA2
12 nosophobia 11.0 BRCA1 BRCA2
13 cancerophobia 11.0 BRCA1 BRCA2
14 rare adenocarcinoma of the breast 11.0 PIK3CA TP53
15 gastric papillary adenocarcinoma 11.0 ERBB2 TP53
16 brca1 hereditary breast and ovarian cancer syndrome 11.0
17 synchronous bilateral breast carcinoma 10.9 BRCA1 BRCA2 TP53
18 mucoepidermoid esophageal carcinoma 10.9 CEACAM5 TP53
19 adult hepatocellular carcinoma 10.9 PIK3CA TP53
20 tuberculous salpingitis 10.9 BRCA1 BRCA2 ERBB2
21 uterine body mixed cancer 10.9 ARID1A ERBB2 TP53
22 breast cystic hypersecretory carcinoma 10.9 CDH1 ERBB2
23 cerebral convexity meningioma 10.9 CDH1 TP53
24 mutagen sensitivity 10.9 BRCA1 BRCA2 TP53
25 papillary serous adenocarcinoma 10.8 BRCA1 KRT7 TP53
26 nephrogenic adenoma of urinary bladder 10.8 KRT7 PAX8
27 bilateral breast cancer 10.8 BRCA1 BRCA2 ERBB2
28 breast medullary carcinoma 10.8 BRCA1 ERBB2
29 breast squamous cell carcinoma 10.8 ERBB2 PIK3CA TP53
30 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.8 ARID1A PIK3CA TP53
31 esophagus adenocarcinoma 10.8 ERBB2 PIK3CA TP53
32 lobular neoplasia 10.8 BRCA1 CDH1 ERBB2
33 breast mucoepidermoid carcinoma 10.8 CEACAM5 ERBB2
34 intracranial chondrosarcoma 10.8 CEACAM5 TP53
35 mixed cell type cancer 10.8 ERBB2 KRT7 TP53
36 granulosa cell tumor of the ovary 10.8 ERBB2 KRT7 TP53
37 acinar cell carcinoma 10.8 BRCA2 KRT7 TP53
38 hidradenocarcinoma 10.8 ERBB2 KRT7 TP53
39 cystadenofibroma 10.8 BRCA1 BRCA2 KRT7
40 vulvar intraepithelial neoplasia 10.8 CDH1 MMP2 TP53
41 bladder squamous cell carcinoma 10.8 ERBB2 PIK3CA TP53
42 cutaneous mucoepidermoid carcinoma 10.8 CEACAM5 KRT7
43 anal gland adenocarcinoma 10.8 CEACAM5 KRT7
44 ovarian clear cell adenocarcinoma 10.8 ARID1A HNF1B PIK3CA
45 bladder benign neoplasm 10.8 KRT7 PAX8
46 sweat gland cancer 10.8 ERBB2 KRT7 TP53
47 peritoneum cancer 10.8 BRCA1 BRCA2 PAX8
48 pharynx cancer 10.8 CDH1 TP53 VEGFA
49 gallbladder squamous cell carcinoma 10.8 CEACAM5 ERBB2 TP53
50 tetraploidy 10.7 BRCA2 TP53

Graphical network of the top 20 diseases related to Ovarian Cancer 1:



Diseases related to Ovarian Cancer 1

Symptoms & Phenotypes for Ovarian Cancer 1

Clinical features from OMIM:

607893

UMLS symptoms related to Ovarian Cancer 1:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.36 ARID1A BRCA1 BRCA2 CDH1 ERBB2 HNF1B

MGI Mouse Phenotypes related to Ovarian Cancer 1:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.37 BRCA2 CDH1 DPH1 ERBB2 HNF1B KRT7
2 cellular MP:0005384 10.35 PHF13 PIK3CA TP53 VEGFA ARID1A BRCA1
3 endocrine/exocrine gland MP:0005379 10.34 ACSBG1 AREG ARID1A BRCA1 BRCA2 CDH1
4 growth/size/body region MP:0005378 10.32 BRCA1 BRCA2 CDH1 DPH1 ERBB2 HNF1B
5 embryo MP:0005380 10.28 ARID1A BRCA1 BRCA2 CDH1 DPH1 ERBB2
6 mortality/aging MP:0010768 10.28 AREG ARID1A BRCA1 BRCA2 CDH1 DPH1
7 cardiovascular system MP:0005385 10.27 AREG ARID1A BRCA1 CDH1 ERBB2 MMP2
8 digestive/alimentary MP:0005381 10.15 AREG BRCA1 BRCA2 CDH1 DPH1 ERBB2
9 integument MP:0010771 10.13 AREG BRCA1 BRCA2 CDH1 DPH1 ERBB2
10 craniofacial MP:0005382 10.1 DPH1 ERBB2 MMP2 PAX8 TP53 VEGFA
11 neoplasm MP:0002006 10.07 VEGFA ARID1A BRCA1 BRCA2 CDH1 DPH1
12 muscle MP:0005369 10.01 ARID1A BRCA1 ERBB2 HNF1B MMP2 PIK3CA
13 limbs/digits/tail MP:0005371 10 BRCA1 BRCA2 DPH1 ERBB2 PAX8 TP53
14 reproductive system MP:0005389 9.93 ACSBG1 AREG ARID1A BRCA1 BRCA2 CDH1
15 normal MP:0002873 9.91 TP53 VEGFA ARID1A BRCA1 BRCA2 CDH1
16 no phenotypic analysis MP:0003012 9.87 ARID1A CDH1 ESS2 PAX8 PIK3CA TP53
17 skeleton MP:0005390 9.65 ARID1A BRCA1 BRCA2 DPH1 ERBB2 MMP2
18 vision/eye MP:0005391 9.23 AREG ARID1A DPH1 MMP2 PAX8 PIK3CA

Drugs & Therapeutics for Ovarian Cancer 1

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
CEA-Scan 18 Immunomedics April 1996
2
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
3
Ethyol 18 AMIFOSTINE Alza December 8, 1995
4
Hycamtin 18 49 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
5
Iressa 18 49 GEFITINIB AstraZeneca May 2003
6
Lynparza 18 49 OLAPARIB AstraZeneca December 2014

Drugs for Ovarian Cancer 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 643)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
3
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 763113-22-0 23725625
4
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
5
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
6
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
7
Tranexamic Acid Approved Phase 4 1197-18-8 5526
8
Aprepitant Approved, Investigational Phase 4,Phase 2,Not Applicable 170729-80-3 151165 6918365
9
Fosaprepitant Approved Phase 4,Phase 2,Not Applicable 172673-20-0 219090
10
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925
11
Peppermint Approved, Nutraceutical Phase 4
12
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 5785 54670067
13
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 11103-57-4, 68-26-8 445354
14
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
15
Substance P Investigational Phase 4,Phase 2,Not Applicable 33507-63-0 44359816
16 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Dexamethasone acetate Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
22 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 taxane Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Ferrous fumarate Phase 4,Not Applicable,Early Phase 1
41 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antifibrinolytic Agents Phase 4
45 Coagulants Phase 4,Phase 2,Not Applicable
46 Hemostatics Phase 4,Phase 2,Not Applicable
47 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 neurokinin A Phase 4,Phase 2,Not Applicable
50 Neurokinin-1 Receptor Antagonists Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2381)
# Name Status NCT ID Phase Drugs
1 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
2 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
3 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
4 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
5 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
6 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
7 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
8 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
9 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
10 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
11 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4 Olaparib
12 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Recruiting NCT03543462 Phase 4
13 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
14 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
15 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
16 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
17 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
18 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
19 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
20 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
21 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
22 Hydralazine Valproate for Ovarian Cancer Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
23 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
24 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
25 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
26 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
27 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
28 Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer Unknown status NCT01628380 Phase 3
29 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
30 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
31 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
32 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
33 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
34 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
35 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy Unknown status NCT02097446 Phase 3
36 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
37 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
38 Violence Against Women and Consequences During Climacteric´s Phase Completed NCT01028118 Phase 3
39 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed NCT01847274 Phase 3 Active comparator: Niraparib;placebo
40 Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
41 Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer Completed NCT00102375 Phase 3 Topotecan
42 Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy Completed NCT00006453 Phase 3 carboplatin;gemcitabine hydrochloride
43 Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer Completed NCT00102414 Phase 3 Gemcitabine
44 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3 chemotherapy
45 High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery Completed NCT00004921 Phase 3 carboplatin;cyclophosphamide;melphalan;paclitaxel
46 Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
47 Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy Completed NCT00312988 Phase 3 Hycamtin;Gemcitabine
48 Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer Completed NCT00426257 Phase 3
49 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
50 Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed NCT00327444 Phase 2, Phase 3 aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Placebo;aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

Search NIH Clinical Center for Ovarian Cancer 1

Cochrane evidence based reviews: ovarian epithelial cancer

Genetic Tests for Ovarian Cancer 1

Genetic tests related to Ovarian Cancer 1:

# Genetic test Affiliating Genes
1 Ovarian Cancer 1 29

Anatomical Context for Ovarian Cancer 1

MalaCards organs/tissues related to Ovarian Cancer 1:

41
Lung, T Cells, Ovary, Testes, Bone, Breast, Bone Marrow

Publications for Ovarian Cancer 1

Articles related to Ovarian Cancer 1:

(show top 50) (show all 2167)
# Title Authors Year
1
The role of the long non-coding RNA TDRG1 in epithelial ovarian carcinoma tumorigenesis and progression through miR-93/RhoC pathway. ( 28984384 )
2018
2
P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling. ( 29343281 )
2018
3
TLR4 and NFI_B signaling is critical for taxol resistance in ovarian carcinoma cells. ( 28771725 )
2018
4
Clitoral priapism due to distant clitoral metastasis of high-grade serous ovarian carcinoma: A case report and review of the literature. ( 29915806 )
2018
5
Integrating the dysregulated inflammasome-based molecular functionome in the malignant transformation of endometriosis-associated ovarian carcinoma. ( 29423077 )
2018
6
Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway. ( 28651497 )
2017
7
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. ( 28882436 )
2017
8
A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase. ( 29200691 )
2017
9
Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line. ( 28251557 )
2017
10
Prognostic value of abnormally expressed lncRNAs in ovarian carcinoma: a systematic review and meta-analysis. ( 28118613 )
2017
11
Cytotoxic activity of genistein-8-C-glucoside form<i>Lupinus luteus</i>L. and genistein against human SK-OV-3 ovarian carcinoma cell line. ( 28111515 )
2017
12
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. ( 27908594 )
2017
13
Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. ( 28639280 )
2017
14
Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors. ( 28065619 )
2017
15
Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma. ( 28668894 )
2017
16
Shotgun Glycomics Identifies Tumor-Associated Glycan Ligands Bound by an Ovarian Carcinoma-Specific Monoclonal Antibody. ( 29101385 )
2017
17
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid Tumors. ( 28264872 )
2017
18
The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma. ( 29040183 )
2017
19
The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma. ( 28428108 )
2017
20
Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. ( 27913862 )
2017
21
Struma Ovarii with Pseudo-Meigs' Syndrome and Raised Cancer Antigen-125 Levels Masquerading as an Ovarian Carcinoma Case report and literature review. ( 28690899 )
2017
22
Discovering the Deregulated Molecular Functions Involved in Malignant Transformation of Endometriosis to Endometriosis-Associated Ovarian Carcinoma Using a Data-Driven, Function-Based Analysis. ( 29113136 )
2017
23
Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma. ( 27941884 )
2017
24
Glycerol-3-phosphate Acyltransferase 1 Promotes Tumor Cell Migration and Poor Survival in Ovarian Carcinoma. ( 28652252 )
2017
25
Overexpression of SIRT1 is Associated With Poor Outcomes in Patients With Ovarian Carcinoma. ( 26862948 )
2017
26
CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma. ( 28346425 )
2017
27
Anti-Yo positive and late-onset paraneoplastic cerebellar degeneration associated with ovarian carcinoma: A case report. ( 28796031 )
2017
28
Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression. ( 28259910 )
2017
29
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection. ( 27362900 )
2017
30
EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. ( 28646021 )
2017
31
The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma. ( 29022892 )
2017
32
The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole. ( 28666422 )
2017
33
The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases. ( 28123552 )
2017
34
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis. ( 28545541 )
2017
35
Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism. ( 27755234 )
2017
36
Dickkopf-4 is frequently overexpressed in epithelial ovarian carcinoma and promotes tumor invasion. ( 28666421 )
2017
37
Upregulation of the lncRNA Meg3 induces autophagy to inhibit tumorigenesis and progression of epithelial ovarian carcinoma by regulating activity of ATG3. ( 28423647 )
2017
38
Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3A year experience. ( 28669065 )
2017
39
ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells. ( 28184931 )
2017
40
Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma. ( 28646019 )
2017
41
The role of miR-372 in ovarian carcinoma cell proliferation. ( 28456593 )
2017
42
Involvement of DPP9 in gene fusions in serous ovarian carcinoma. ( 28893231 )
2017
43
Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor I+ in high-grade serous ovarian carcinoma. ( 28414091 )
2017
44
Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. ( 28464843 )
2017
45
Reversion of P-gp-Mediated Drug Resistance in Ovarian Carcinoma Cells with PHPMA-Zosuquidar Conjugates. ( 28409628 )
2017
46
[Risk factors of endometriosis associated ovarian carcinoma in women aged 45 years and older]. ( 28545269 )
2017
47
Antibody-mediated depletion of immunosuppressive factors from ovarian carcinoma-associated ascites for investigation of paracrine versus autocrine effects. ( 28159551 )
2017
48
Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. ( 29042553 )
2017
49
[miR-218 Promoted the Apoptosis of Human Ovarian Carcinoma Cells via Suppression of the WNT/I^-Catenin Signaling Pathway]. ( 28900081 )
2017
50
Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy. ( 28160193 )
2017

Variations for Ovarian Cancer 1

Expression for Ovarian Cancer 1

Search GEO for disease gene expression data for Ovarian Cancer 1.

Pathways for Ovarian Cancer 1

Pathways related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 AREG BRCA1 ERBB2 PIK3CA TP53 VEGFA
2
Show member pathways
12.67 AREG BRCA2 CDH1 ERBB2 PAX8 PIK3CA
3
Show member pathways
12.58 ARID1A BRCA1 BRCA2 CDH1 ERBB2 PIK3CA
4 12.58 BRCA2 CDH1 ERBB2 MMP2 PAX8 PIK3CA
5 12.4 BRCA1 ERBB2 PIK3CA TP53 VEGFA
6
Show member pathways
12.4 AREG CDH1 ERBB2 MMP2 PIK3CA TP53
7
Show member pathways
12.36 AREG ERBB2 PIK3CA TP53 VEGFA
8 12.18 ERBB2 MMP2 PIK3CA TP53 VEGFA
9 12.07 CDH1 MMP2 TP53 VEGFA
10 11.99 BRCA1 BRCA2 CDH1 TP53 VEGFA
11 11.98 MMP2 PIK3CA TP53 VEGFA
12
Show member pathways
11.89 BRCA1 BRCA2 CDH1 ERBB2 MMP2 PIK3CA
13 11.77 ERBB2 PIK3CA VEGFA
14 11.76 MMP2 PIK3CA VEGFA
15
Show member pathways
11.68 BRCA1 BRCA2 TP53
16 11.62 BRCA1 ERBB2 PIK3CA TP53
17 11.56 ERBB2 PIK3CA TP53
18 11.44 BRCA1 TP53 VEGFA
19 11.42 CDH1 ERBB2 MMP2 TP53 VEGFA
20 11.17 ARID1A BRCA1 ERBB2 PIK3CA TP53
21 11.16 CDH1 ERBB2 PIK3CA

GO Terms for Ovarian Cancer 1

Cellular components related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 AREG ARID1A BRCA1 BRCA2 DPH1 ERBB2

Biological processes related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.83 BRCA1 ERBB2 HNF1B TP53 VEGFA
2 cell proliferation GO:0008283 9.8 AREG BRCA2 DPH1 ERBB2 TP53
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.65 AREG TP53 VEGFA
4 positive regulation of transcription, DNA-templated GO:0045893 9.5 ARID1A BRCA1 BRCA2 CDH1 HNF1B PAX8
5 mesonephric tubule development GO:0072164 9.46 HNF1B PAX8
6 pronephros development GO:0048793 9.37 HNF1B PAX8
7 cellular response to indole-3-methanol GO:0071681 9.32 BRCA1 CDH1
8 chordate embryonic development GO:0043009 9.26 BRCA1 BRCA2
9 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.16 HNF1B PAX8
10 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53

Molecular functions related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 8.92 BRCA1 HNF1B PAX8 TP53

Sources for Ovarian Cancer 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....